PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME

Respiratory infections are frequent in children; consequently evaluation of prophylactic effectiveness of immunomodulators is needed. Objective: to evaluate of clinical, immunological efficacy and safety of pidotimod in complex treatment of children with acute respiratory infections (ARI) and obstru...

Full description

Saved in:
Bibliographic Details
Main Authors: E. E. Lokshina, O. V. Kravchenko, O. V. Zaytseva
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2011-01-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/537
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849242297644875776
author E. E. Lokshina
O. V. Kravchenko
O. V. Zaytseva
author_facet E. E. Lokshina
O. V. Kravchenko
O. V. Zaytseva
author_sort E. E. Lokshina
collection DOAJ
description Respiratory infections are frequent in children; consequently evaluation of prophylactic effectiveness of immunomodulators is needed. Objective: to evaluate of clinical, immunological efficacy and safety of pidotimod in complex treatment of children with acute respiratory infections (ARI) and obstructive syndrome. Methods: patients 3–10 years old hospitalized with ARI and obstructive syndrome participated the study. Children from first group (n = 30) were treated with pidotimod 400 mg 2 times daily during 14 days, children from control group (n = 30) received standard treatment without immunomodulatory agent. Dynamics of clinical course of a disease, immunological indices of blood (IL 2, 4 and 8, interferon α  and γ, IgA, M, G and total IgЕ) and swabs from mucous tunica of nasopharynx (sIgA) was estimated. The cases of recurrent ARIs during 12 months after the beginning of a study were controlled. Results: treatment with pidotimod induced statistically significant decrease of cytokines levels (IL 2, IL 8, and interferon γ) and increase of sIgA. The rate of recurrent ARIs during 12 months after the beginning of a study was lower than in control group. Recurrent episodes of bronchial obstruction occurred rarely. Conclusion: pidotimod has high clinical and immunological effectiveness and safety in treatment of children with ARI and concomitant obstructive syndrome.
format Article
id doaj-art-b1778bcb5c884662b99b25dd9c3de5a2
institution Kabale University
issn 1682-5527
1682-5535
language English
publishDate 2011-01-01
publisher "Paediatrician" Publishers LLC
record_format Article
series Вопросы современной педиатрии
spelling doaj-art-b1778bcb5c884662b99b25dd9c3de5a22025-08-20T03:59:52Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352011-01-011013441537PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROMEE. E. Lokshina0O. V. Kravchenko1O. V. Zaytseva2Moscow State University of Medicine and DentistryMoscow State University of Medicine and DentistryMoscow State University of Medicine and DentistryRespiratory infections are frequent in children; consequently evaluation of prophylactic effectiveness of immunomodulators is needed. Objective: to evaluate of clinical, immunological efficacy and safety of pidotimod in complex treatment of children with acute respiratory infections (ARI) and obstructive syndrome. Methods: patients 3–10 years old hospitalized with ARI and obstructive syndrome participated the study. Children from first group (n = 30) were treated with pidotimod 400 mg 2 times daily during 14 days, children from control group (n = 30) received standard treatment without immunomodulatory agent. Dynamics of clinical course of a disease, immunological indices of blood (IL 2, 4 and 8, interferon α  and γ, IgA, M, G and total IgЕ) and swabs from mucous tunica of nasopharynx (sIgA) was estimated. The cases of recurrent ARIs during 12 months after the beginning of a study were controlled. Results: treatment with pidotimod induced statistically significant decrease of cytokines levels (IL 2, IL 8, and interferon γ) and increase of sIgA. The rate of recurrent ARIs during 12 months after the beginning of a study was lower than in control group. Recurrent episodes of bronchial obstruction occurred rarely. Conclusion: pidotimod has high clinical and immunological effectiveness and safety in treatment of children with ARI and concomitant obstructive syndrome.https://vsp.spr-journal.ru/jour/article/view/537childrenacute respiratory infectionsobstructive syndromepidotimodtreatment
spellingShingle E. E. Lokshina
O. V. Kravchenko
O. V. Zaytseva
PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
Вопросы современной педиатрии
children
acute respiratory infections
obstructive syndrome
pidotimod
treatment
title PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
title_full PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
title_fullStr PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
title_full_unstemmed PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
title_short PIDOTIMOD IN TREATMENT OF CHILDREN WITH ACUTE RESPIRATORY INFECTION WITH CONCOMITANT RECURRENT OBSTRUCTIVE SYNDROME
title_sort pidotimod in treatment of children with acute respiratory infection with concomitant recurrent obstructive syndrome
topic children
acute respiratory infections
obstructive syndrome
pidotimod
treatment
url https://vsp.spr-journal.ru/jour/article/view/537
work_keys_str_mv AT eelokshina pidotimodintreatmentofchildrenwithacuterespiratoryinfectionwithconcomitantrecurrentobstructivesyndrome
AT ovkravchenko pidotimodintreatmentofchildrenwithacuterespiratoryinfectionwithconcomitantrecurrentobstructivesyndrome
AT ovzaytseva pidotimodintreatmentofchildrenwithacuterespiratoryinfectionwithconcomitantrecurrentobstructivesyndrome